ライフサイエンスコーパス: decease

1 ationships by someone who evidently knew the deceased.

2 2) detectable, 3) lost to follow-up, and 4) deceased.

3 tients were transplanted and 14% of patients deceased.

4 eased whereas only 28% below the cutoff were deceased.

5 At the study conclusion, 6 patients were deceased, 28 were discharged, and 26 remained admitted.

6 Following identification of deceased ACM probands possessing ANK2 rare variants and

7 he Pediatric Cardiac Genomics Consortium and deceased adults from Genotype-Tissue Expression.

8 Health Service - Increased Risk designated, deceased after cardiac death, or deceased after cerebrov

9 designated, deceased after cardiac death, or deceased after cerebrovascular accident.

10 In a convenience sample of 266 deceased American football players from the Veterans Aff

11 ethnic minorities, get waitlisted and pursue deceased and living donor kidney transplant (DDKT and LD

12 mission, 5.0% had stable disease, 28.1% were deceased, and 11.7% were on active or palliative treatme

13 rcumstances of death, medical history of the deceased, and results of genetic testing may reveal a di

14 ents (32%) with grade 3-4 neurotoxicity were deceased at database closure, whereas none died with neu

15 who underwent LVMR was 848 and 99(12%) were deceased at follow-up (FU).

16 ncluded in the initial randomized study were deceased at the end of 2017.

17 lization, intensive care unit admission, and deceased based on a short-term follow-up.

18 e studied a national cohort of all US adult, deceased brain dead donor, isolated livers available for

19 Three of the 4 were deceased by the end of the study.

20 Deceased CFLD patients had lower platelet counts than th

21 for fathers were having said farewell to the deceased child in the way they wanted (P = .00) and feel

22 d to determine the causes of mortality among deceased children using verbal autopsy.

23 acted from all available clinical records of deceased children, and relevant maternal health records

24 Deceased coinfected patients had higher initial CD4 coun

25 Deceased coinfected patients had higher initial CD4 coun

26 Lung tissue obtained at autopsy from three deceased Covid-19 patients was processed for hyaluronan

27 uded patients with contraindications to both deceased donation (including infection, malignancy, card

28 shown promise as effective tools to promote deceased donation and expand living donor transplantatio

29 There was early evidence of recovery of deceased donation in the United States and United Kingdo

30 sed donor aged 60 to 79 years and 128 from a deceased donor >=80 years.

31 ed on recipients' geographic distance from a deceased donor ("acuity circles").

32 ed on recipients' geographic distance from a deceased donor (acuity circles [ACs]).

33 vised kidney allocation system that includes deceased donor (DD) kidneys as chain-initiating kidneys

34 higher for recipients of a standard criteria deceased donor (hazard ratio, 1.1; 95% confidence interv

35 y anatomy), and (3) a patient simulated by a deceased donor (high-fidelity anatomy).

36 t kidney transplantation from an HCV-viremic deceased donor (median kidney donor profile index, 53%)

37 a kidney transplant from a standard criteria deceased donor (n = 1523) or from a living donor (n = 13

38 ransplant Recipients, we analyzed n = 156069 deceased donor adult kidney transplants occurring from 2

39 aiting list, 1084 received a first KT from a deceased donor aged 60 to 79 years and 128 from a deceas

40 The reduction was different for deceased donor and living donor liver transplantation an

41 rfusion biopsy associate with outcomes after deceased donor but not living donor renal transplants, t

42 relative graft failure risk associated with deceased donor characteristics.

43 video that featured registered organ donors, deceased donor families, and transplant recipients.

44 In the United States, the number of deceased donor hearts available for transplant is limite

45 ction of graft survival when a kidney from a deceased donor is transplanted into a recipient, with a

46 offs associated with different approaches to deceased donor kidney allocation in terms of quality-adj

47 haracterized several important predictors of deceased donor kidney discard.

48 Deceased donor kidney disposition was determined from sm

49 anel (UNOS-CPRA), using predicted and actual deceased donor kidney offers for a cohort of 24 282 cand

50 ric deceased donor kidneys could enlarge the deceased donor kidney pool.

51 intraoperative real time assessment tool for deceased donor kidney quality and function in human kidn

52 phic differences in transplant rates because deceased donor kidney supply and demand differ across th

53 based study included patients who received a deceased donor kidney that had been biopsied before impl

54 minimum amount of benefit we require from a deceased donor kidney to allocate it for a particular in

55 have expressed concerns regarding decreased deceased donor kidney transplant (DDKT) rates for pediat

56 ranular, single-center data on 109 cPRA 100% deceased donor kidney transplant (DDKT) recipients to st

57 offer decline, 43.0% of decliners received a deceased donor kidney transplant (DDKT), 6.3% received l

58 52 [95% CI, 0.51 to 0.54]); and receipt of a deceased donor kidney transplant (HR, 0.44 [95% CI, 0.44

59 All patients receiving a deceased donor kidney transplant during a recent 10-year

60 All deceased donor kidney transplant implantation biopsies f

61 s showed that PAK after either a living or a deceased donor kidney transplant is associated with incr

62 F and graft loss in pediatric and adolescent deceased donor kidney transplant recipients aged 21 year

63 Similarly, deceased donor kidney transplant volume dropped from 367

64 rthotopic heart transplant, the second had a deceased donor kidney transplant, and the third had a pa

65 ney transplant, and 49 290 (3.3%) received a deceased donor kidney transplant.

66 ing donor kidney transplant, or receipt of a deceased donor kidney transplant.

67 % [95% CI, -2.4% to -2.3%]; and receipt of a deceased donor kidney transplant: -4.3% [95% CI, -4.4% t

68 ft function (DGF) remains a major concern in deceased donor kidney transplantation (DDKT).

69 Geographic disparities in access to deceased donor kidney transplantation persist in the Uni

70 e differences in the adjusted probability of deceased donor kidney transplantation persist under KAS,

71 within 3 years of transplantation in 19 450 deceased donor kidney transplantation recipients with Me

72 m initiation of dialysis to placement on the deceased donor kidney transplantation waiting list, rece

73 tion was less frequent, some restrictions to deceased donor kidney transplantation were reported by 8

74 ach center, we calculated the probability of deceased donor kidney transplantation within 3 years of

75 wn if the pattern holds for living donor and deceased donor kidney transplantation, varies by facilit

76 a safe and feasible approach to treat DGF in deceased donor kidney transplantation.

77 er, disparities in waiting times persist for deceased donor kidney transplantation.

78 We investigated 375 deceased donor kidney transplantations, which had DSA as

79 Of 7668 deceased donor kidney transplants between 1997 and 2014,

80 Between 2006 and 2014, 81 945 adult solitary deceased donor kidney transplants were performed in the

81 Candidates received deceased donor kidney transplants within 3 years of wait

82 I], 0.92-0.95), higher yearly volume (per 10 deceased donor kidney transplants; aOR, 1.08, 95% CI, 1.

83 allograft survival compared with receiving a deceased donor kidney.

84 From 2000 to 2018, 21 731 deceased donor kidneys (averaging 1144 kidneys per year)

85 rates underestimate the underutilization of deceased donor kidneys and more research is needed to op

86 Deceased donor kidneys are preserved in cold hypoxic con

87 A significant proportion of procured deceased donor kidneys are subsequently discarded.

88 ization approach makes more efficient use of deceased donor kidneys but reduces access to transplanta

89 It has been suggested that deceased donor kidneys could be used to initiate chains

90 Increased use of pediatric deceased donor kidneys could enlarge the deceased donor

91 K Transplant Registry data were collected on deceased donor kidneys implanted between November 1, 201

92 and US transplant registries, including all deceased donor kidneys recovered from 2006 to 2017, were

93 ed a sustained increase in the proportion of deceased donor kidneys that are retrieved but not utiliz

94 a significant number of potentially useable deceased donor kidneys will be discarded because they ar

95 Deceased donor kidneys with diffuse GFT appear to be saf

96 common complication after transplantation of deceased donor kidneys, affects both short- and long-ter

97 n purposes, of the "top 20%" designation for deceased donor kidneys.

98 African ancestry and alter the allocation of deceased donor kidneys.

99 In deceased donor KT (DDKT) recipients, the prevalence was

100 We studied deceased donor KT recipients (n = 120 818) and waitliste

101 of pandemic, waitlist priority when modeling deceased donor KT) had greatest influence on benefit/har

102 y transplantation were reported by 84.0% and deceased donor liver by 73.3%; more stringent restrictio

103 nd recipient characteristics associated with deceased donor liver organ offers for children who died

104 mented Share 35 on June 18, 2013, to broaden deceased donor liver sharing within regional boundaries.

105 een living donor liver transplant (LDLT) and deceased donor liver transplant (DDLT) at a single cente

106 Patients were excluded if they received a deceased donor liver transplant.

107 categorized into predominantly LDLT (18) or deceased donor liver transplantation (6), and high- (10)

108 er Share 35 impacted geographic disparity in deceased donor liver transplantation (DDLT) across donat

109 g donor liver transplantation, its impact in deceased donor liver transplantation (DDLT) is unclear.

110 with univariate competing risk regressions (deceased donor liver transplantation as the competing ri

111 ed for patients 18 years or older listed for deceased donor liver transplantation with stage II HCC e

112 ysis and Research database was evaluated for deceased donor liver transplants between 2006 and 2016 a

113 ion of DHOPE-COR-NMP increased the number of deceased donor liver transplants by 20%.

114 The UNOS database was reviewed for deceased donor liver transplants from March 2002 - Decem

115 ) is 1 strategy for maximizing the number of deceased donor liver transplants.

116 ta (07/2013-06/2017) for 27 334 transplanted deceased donor livers and 44 652 incident waitlist candi

117 Around 1600 deceased donor livers are transplanted annually.

118 Regional allocation of deceased donor livers has led to variable wait times for

119 years with chronic liver disease, listed for deceased donor livers January 1, 2005-December 31, 2017.

120 gan Sharing database was queried to identify deceased donor livers procured from 2016 to 2019 (n = 30

121 Of 37 333 deceased donor livers transplanted, 6.3% met our strict

122 nsecutive adult patients who underwent first deceased donor LT at a single center between August 2008

123 ients who underwent a primary, single-organ, deceased donor LT from January 1, 2008 to January 31, 20

124 rnational, multicenter cohort study of adult deceased donor LT requiring AC.

125 recently introduced as alternative to whole deceased donor LT, but it is limited by poor availabilit

126 rsal approval rate allowing prompt access to deceased donor LT.

127 waitlist registrations, waitlist mortality, deceased donor LTs (DDLT), and living donor LTs (LDLT) 3

128 We examined deceased donor offers that were ultimately split between

129 ncreasingly in the assessment of higher risk deceased donor organs and to facilitate prolonged organ

130 Considering the perpetual scarcity of deceased donor organs, Kates et al present a viewpoint t

131 ntages and a shortage of the availability of deceased donor organs.

132 eys in children may help expand the existing deceased donor pool; however, studies examining the long

133 context (eg, country size, effectiveness of deceased donor program) and ethical and legal considerat

134 es to match 148 en bloc with 581 non-en bloc deceased donor recipients (matching variables: transplan

135 in reducing delayed graft function (DGF) in deceased donor renal transplantation, we undertook the e

136 in patients on the active waiting list for a deceased donor SOT and recipients with a functioning SOT

137 In the 2010-2013 multicenter Deceased Donor Study of 2430 kidney transplant recipient

138 , but not cohort B, had significantly higher deceased donor transplant and offer acceptance rates dur

139 ries for standardized waitlist mortality and deceased donor transplant rate ratios, along with an ind

140 any organ was recovered), offer acceptance, deceased donor transplant rates, and waitlist mortality

141 While complete suspension of deceased donor transplantation was less frequent, some r

142 dard (n = 25) and extended-criteria (n = 14) deceased donor transplants.

143 is not inferior to that of HLA well-matched deceased donor transplants.

144 A deceased donor vessel graft was used as conduit in combi

145 profit vs all nonprofit dialysis facilities: deceased donor waiting list (hazard ratio [HR], 0.36 [95

146 , 121 680 patients (8.2%) were placed on the deceased donor waiting list, 23 762 (1.6%) received a li

147 es for each outcome vs nonprofit facilities (deceased donor waiting list: -13.2% [95% CI, -13.4% to -

148 plant, 16,490 (3%) had been removed from the deceased donor waitlist, 17,010 (3%) were inactive on th

149 nd the final recipient was selected from our deceased donor waitlist.

150 r, adjusted odds ratio [aOR] = 0.640.770.91; deceased donor, aOR = 0.710.810.92).

151 recipients (living donor, aOR=0.640.770.91; deceased donor, aOR=0.710.810.92).

152 Recipients of a standard criteria deceased donor, compared with recipients of a living don

153 on the same day: 1 from a standard criteria deceased donor, the other from a living donor.

154 port of a successfully completed, deliberate deceased donor-initiated chain, which was made possible

155 The gain of implementing deceased donor-initiated chains was measured with an alg

156 splants-1021 with a living donor, 532 with a deceased donor-under our RDP protocol.

157 Many deceased-donor and living-donor kidney transplants (KTs)

158 Data were extracted for 12 902 deceased-donor kidney alone transplants performed in all

159 at transplant centers and potentially reduce deceased-donor kidney discard rate.

160 The tool was tested on 1000 deceased-donor kidney offers in 2016.

161 liest of graft failure or patient death) for deceased-donor kidney transplant (DDKT) recipients (n =

162 th a functioning kidney, and categorized as: deceased-donor kidney transplant alone (DD-KA, 68%), liv

163 The cohort consisted of adult deceased-donor kidney transplant recipients transplanted

164 Allocation for pediatric deceased-donor kidney transplantation (pDDKT) in the Uni

165 ansplant MSC administration is unfeasible in deceased-donor kidney transplantation.

166 ns, waitlist mortality, and living-donor and deceased-donor kidney transplants (LDKT/DDKT) March 15-A

167 mab in preventing acute AMR in recipients of deceased-donor kidney transplants with preformed donor-s

168 ing and posttransplant survival outcomes for deceased-donor kidney transplants.

169 nsplant Recipients, we studied 110,019 adult deceased-donor KT recipients between 2005 and 2017.

170 egistered on a common WL and prioritized for deceased-donor liver allocation.

171 t-transplant outcome in 12,974 recipients of deceased-donor livers (January 1, 2004, to December 31,

172 standard for selecting patients with HCC for deceased-donor LT (DDLT).

173 We investigated whether deceased-donor lung transplant (LT) rates differed subst

174 A patient received a deceased-donor small intestinal and colon allograft with

175 ministering MSCs on the day of transplant in deceased-donor transplant recipients and indicate that c

176 y on long-term kidney graft survival in 3237 deceased-donor transplants.

177 1, 2017, 20 transplant programs performed 72 deceased-donor VCA transplants, with organs donated by 7

178 examined the variability in DCDD donors/all deceased donors (%DCDD) across DSAs.

179 examined the variability in DCDD donors/all deceased donors (%DCDD) across DSAs.

180 nsplant group, comparisons were made between deceased donors (n = 39), live donor HLA-compatible (n =

181 splantation Network data to characterize VCA deceased donors (n = 66 of 70) in the United States from

182 January 1, 2000, and December 31, 2015, from deceased donors aged 50 y and older, for which data on r

183 showed that, with a pool of 69 kidneys from deceased donors and 16 pairs enrolled in the kidney pair

184 A-compatible live donors, compared to 75% in deceased donors and 53% in HLA-incompatible live donors,

185 We genotyped 477 pairs of deceased donors and first kidney transplant recipients w

186 transplantation is limited by the number of deceased donors and the necessity of immunosuppression.

187 lograft failure in kidneys transplanted from deceased donors and the safety of living kidney donation

188 3a and C5a in donor urine on outcomes of 469 deceased donors and their corresponding 902 kidney recip

189 n early recovery of the number of living and deceased donors and transplants has ensued.

190 Despite KT from octogenarian deceased donors being associated with reduced graft surv

191 plant Network (OPTN) database, we identified deceased donors from 2002 to 2017 who had one kidney all

192 Based on a review of 577 consecutive deceased donors from the Swisstransplant Donor-Registry,

193 demonstrated a low prevalence of ZIKV among deceased donors in our community.

194 For recipients of deceased donors in the third/fourth transplant group, th

195 sis and Research files was undertaken on all deceased donors in the United States with at least 1 sol

196 om hepatitis C virus-positive (HCV-positive) deceased donors into HCV-negative recipients is a recent

197 % (6/39) of living donors and 8.5% (4/47) of deceased donors of recipients at our institution (P = .5

198 Deceased donors recovered dropped from 260 to 163 (-45%)

199 compatible live donors and extended-criteria deceased donors should be considered.

200 imulated the allocation of kidneys from 2200 deceased donors to a waiting list of 5500 patients and p

201 All deceased donors who donated at least one organ were incl

202 Kidneys from deceased donors with acute kidney injury (AKI) are more

203 ansplant surgeons are more likely to discard deceased donors with acute kidney injury (AKI) versus wi

204 has demonstrated similar graft survival for deceased donors with AKI versus donors without AKI.

205 ude that transplanting selected kidneys from deceased donors with AKI with preimplantation biopsy sho

206 patients transplanted utilizing kidneys from deceased donors with AKI.

207 seven centers to transplant 30 kidneys from deceased donors with HCV viremia into HCV-uninfected rec

208 The outcomes of recipients of organs from deceased donors with ITP recorded in the UK Transplant R

209 Organs from the 18- to 34-year-old deceased donors with PHS risks (but relatively few medic

210 er accepting heart or liver transplants from deceased donors with SARS-CoV-2 infection.

211 Kidneys transplanted from deceased donors with serum creatinine-defined acute kidn

212 lines stating that all organs from potential deceased donors with severe acute respiratory syndrome c

213 Among deceased donors, 8.1% (17/208) had detectable BKV DNA in

214 eved that ApoL1 testing should be done on AA deceased donors, and older age (aOR, 1.85; 95% CI, 1.03,

215 Twenty-two VCAs were procured from 21 deceased donors, resulting in 109 non-VCA organs transpl

216 Among 52,184 deceased donors, the %DCDD varied widely across DSAs, wi

217 Among 52 184 deceased donors, the %DCDD varied widely across DSAs, wi

218 occurred in 23 (24%) kidney recipients from deceased donors.

219 02) were associated with interest in testing deceased donors.

220 after implementing rotational positioning of deceased donors.

221 ts received kidneys with diffuse GFT from 16 deceased donors.

222 gan types and are made possible primarily by deceased donors.

223 of 80 or greater that were procured from 338 deceased donors.

224 s were compared with those from well-matched deceased donors.

225 received uteri from living donors and 2 from deceased donors.

226 An OPO's organ donation rate (deceased donors/potential donors) and organ transplant r

227 ly higher density in live versus prematurely deceased females indicating a potentially mutualistic as

228 relatives, and second-degree relatives of a deceased first-degree relative suspected of having an in

229 In a convenience sample of deceased football players who donated their brains for r

230 e neuropathological and clinical features of deceased football players with CTE.

231 bserved using tools to clean the corpse of a deceased group member.

232 The mean age in the deceased group was 70.7 years, significantly higher than

233 -1 cells, leading to a lower glucose uptake (deceased > 40%) and glycolysis capacity (reduced approxi

234 The deceased had fewer teeth and more oral infections.

235 e eligible to receive a kidney or liver from deceased HIV-positive donors without active infections o

236 ould take for them to obtain a kidney from a deceased human donor.

237 ical and continuing shortage of kidneys from deceased human donors.

238 xpression patterns in the internal organs of deceased humans.

239 is enriched within the resting follicle and deceases immediately prior to HFSC activation.

240 post-mortem medical procedure performed on a deceased individual with the primary goal of collecting

241 Information for deceased individuals was provided by relatives living in

242 a unique collection of samples obtained from deceased individuals with clinically and histopathologic

243 Patients with cancer comprised 8.4% of deceased individuals(1).

244 sponses to the nucleocapsid were elevated in deceased individuals.

245 ithin the article we present sketches of the deceased international board members of the AJO, particu

246 ant plasma and urine samples from living and deceased kidney donors and performed BKV polymerase chai

247 nsplant CMV prevention strategy via matching deceased kidney donors and recipients by CMV serostatus.

248 r Risk Index (KDRI) is a score applicable to deceased kidney donors which reflects relative graft fai

249 es that are comparable to those derived from deceased kidney donors while improving upon several prob

250 ction immunosuppression on the risk of AR in deceased kidney recipients based on pretransplant risk o

251 Racial/ethnic minorities have lower rates of deceased kidney transplantation (DDKT) and living donor

252 From one of the largest series of deceased LTx for this indication, we conclude that it is

253 10-64 y; median, 29.6 y) received bilateral deceased lung transplants for pulmonary chronic GVHD bet

254 worsened (liver transplantation [LT] (n=5), deceased (n=2)).

255 e study, we show increased PAPR2 expression, deceased NAD+, and SIRT1, increased PGC-1alpha acetylati

256 causes of death in stillborn fetuses and in deceased neonates and children younger than 5 years, to

257 Other tissues of the deceased newborn tested positive by qPCR for Epstein-Bar

258 ous viral particles in different organs of a deceased newborn with Congenital Zika Syndrome.

259 e (PPY)-producing gamma-cells, obtained from deceased non-diabetic or diabetic human donors, can be l

260 initial photocurrent density (>8 mA cm(-2)) deceased only 15% or 33% during continuous operation for

261 Grafts can be obtained from deceased or living donors, with different logistical req

262 ients (P < 0.01), increasing awareness about deceased organ donation (P < 0.01), and advertising for

263 , but it was not associated with the rate of deceased organ donation or median waiting time for trans

264 th perception contributes to the low rate of deceased organ donation that has been observed amongst A

265 When blood supply in a deceased organ donor stops, ischemic injury starts.

266 Compared with the standard risk deceased organ donor, the PHS donor was younger, male, d

267 olations per year over the last 3 years from deceased organ donors and pancreatectomized patients, re

268 After the 2013 modification, over 20% of all deceased organ donors in the United States were identifi

269 th the levels of cf-mt-DNA elevated in older deceased organ donors, and with the isolated cf-mt-DNA c

270 the United States and may account for 3% of deceased organ donors.

271 Families play an essential role in deceased organ procurement.

272 To make MSCs a therapeutic option also for deceased organ recipients, we tested whether MSC infusio

273 score of 7-15 (P = 0.021) and a score of 16+/deceased (P = 0.007).

274 xamined the dorsolateral frontal cortex from deceased participants within a community-based aging coh

275 esponsibility, 2) how they interact with the deceased patient in the ICU, 3) how family members descr

276 The combined intensive care unit group and deceased patients had significantly more consolidation,

277 Data on deceased patients who initially were followed up prospec

278 11 deceased patients with COVID-19 (10 of whom were selecte

279 For deceased patients, mean SAPS II was 42 +/- 13.2 (range,

280 s and 21 (20%) from oral swab specimens from deceased patients.

281 the likely cause of death for 44.7% of these deceased patients.

282 served in the histological assessment of two deceased patients.

283 Two studies included relatives of dying/deceased patients.

284 ollected and compared between discharged and deceased patients.

285 ng donation, or permitting donation when the deceased refused it.

286 donation themselves, donate the organs of a deceased relative, or support a transition to an "opt-ou

287 ndoffspring survival with living or recently deceased reproductive and postreproductive grandmothers,

288 staff returned questionnaires regarding 1384 deceased residents (response rate 81%).

289 uthorize organ procurement in the absence of deceased's preferences and the default is not to remove

290 social exposure to others who are morbid or deceased shows considerable variation in how the epidemi

291 rental consanguinity and similarly affected, deceased siblings, suggesting autosomal recessive inheri

292 cochemical parameter allowing the health and decease status of the cell to be measured.

293 569 million people live in those areas with deceasing SWA or TWS trends in 2015.

294 increase schooling, decrease depression, and decease transactional sex showed the largest reduction i

295 studied kidneys that had been acquired from deceased United States donors for transplantation that w

296 ailure for recipients of a standard criteria deceased versus living donor.

297 ceiver operating characteristics cutoff were deceased whereas only 28% below the cutoff were deceased

298 amilies can overrule the known wishes of the deceased, which can mean preventing donation, or permitt

299 FLD (143 versus 258 U/L, P = 0.004) or those deceased with no CFLD (143 versus 327U/L, P = 0.006).

300 d on their own wishes or what they think the deceased would have wanted.